David Ochoa Profile picture
Platform coordinator at @opentargets
Oct 6, 2023 7 tweets 3 min read
Our retrospective on the availability of genetic support for all FDA approvals during the last decade is now available in @NatRevDrugDisc 🧵 bit.ly/3Q5WIvo
Annual breakdown of drugs approved by the FDA from 2013 to 2022 based on the presence and timing of support from genetic evidence. The depicted categories are drugs with prior genetic evidence, drugs with any genetic evidence, drugs without genetic evidence and drugs with non-human targets or an unknown mechanism of action. The numbers of drugs are shown in brackets. For additional data and details of the analysis, see Supplementary information. Data source: Open Targets Platform (June 2023) Last year, we reported two-thirds of 2021 approved drugs presented genetic evidence between the intended pharmacological target and the indication go.nature.com/46ExIAY
Supporting human genetic evidence for new drugs approved by the FDA in 2021. Availability of genetic evidence implicating each of the 50 drug targets (columns) as likely causal genes for the disease for which the drug is indicated. Genetic data sources are stratified (rows) based on the predominant nature of the genetic information. Evidence is classified based on whether it directly supports the gene–indication pair or any of the closely related phenotypes or proteins. See Supplementary information for details and an expanded figure. Data source: Open Targets Platform (November 2021).
Apr 28, 2022 6 tweets 5 min read
Big leap for the @OpenTargets platform. Gene burden from 450k+ @uk_biobank exomes from @AstraZeneca and @Regeneron, ClinVar structural variants, NLP classification of clinical trials stop reasons and drug label indications,etc. Systematically filling the gaps one-by-one 🧵 On our mission to identify potential causal targets from genetics 🧬, the strongly-powered @uk_biobank burden tests provide us an opportunity to close the gap between rare disease variation, and common variation from GWAS studies - as post-processed by the Genetics Portal
Aug 12, 2021 5 tweets 4 min read
Systematically overlaying likely pathogenic variants over @DeepMind #AlphaFold predicted structures provides a unique opportunity to dive into the mechanisms of disease.

Here, NOD2 inflammatory disease-causing variants on the experimentally unresolved structure. 1/5 Data-wise, the @OpenTargets Platform and Genetics Portal provide a comprehensive aggregation of disease-causing variants post-processed from other great resources like @GWASCatalog or @NCBI_Clinical ClinVar (via @evarchive) among others
platform.opentargets.org/evidence/ENSG0…
2/5